Logo

Mainz Biomed: Frank Krieg-Schneider

Aug 03, 2022

Mainz Biomed has appointed Frank Krieg-Schneider as VP of development. He will lead commercialization efforts across the company's portfolio of cancer detection products including its flagship ColoAlert test. Krieg-Schneider most recently led the clinical diagnostics division at Germany's R-Biopharm. He also previously served as CEO of molecular diagnostics firm GNA Biosolutions, and prior to that spent two decades in senior management and executive roles with Qiagen, including head of R&D for diagnostic sample preparation and head of global strategic alliances.

Breaking News
The Scan

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.

Neurological Outcomes Linked to Innate Immune Features After Cardiac Arrest

Researchers reporting in Med dig into immune features found a few hours after cardiac arrest that correspond with neurological outcomes.

Mouse Study Finds Circadian Rhythm-Related Gene Expression Changes Linked to Sleep Apnea

A paper in PLOS Biology reveals tissue-specific circadian rhythm and gene expression patterns in an intermittent hypoxia-based mouse model of obstructive sleep apnea.

Polygenic Risk Score to Predict Preeclampsia, Gestational Hypertension in Pregnant Women

Researchers in Nature Medicine provide new mechanistic insights into the development of hypertensive disorders of pregnancy, which may help develop therapeutics.